Overview

Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft

Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 12-month prophylactic treatment with pantoprazole is superior to 1-month therapy without major cardiovascular events (MACE) increased significantly, in prevention of dual antiplatelet therapy (DAPT)-induced upper gastrointestinal (GI) mucosal injury after coronary artery bypass graft (CABG) surgery. The potentially serious harm of DAPT on gastroduodenal mucosa will be assessed by esophagogastroduodenoscopy (EGD).
Phase:
Phase 4
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Pantoprazole
Proton Pump Inhibitors